Global Non-insulin Therapies for Diabetes Market, By Product (Oral {Thiazolidinediones (TZDs), Insulin secretagogues, Alpha-glucosidase inhibitors (AGIs), Sulfonylureas, Dipeptidyl peptidase-4 (DPP-4) inhibitors, Sodium-glucose cotransporter-2 (SGLT2) inhibitors, Glinides/Meglitinides, Metformin, Biguanides, & Others} Injectable {Glucagon-like peptide-1 (GLP-1) agonists, Amylin Agonists, & Others}), By Distributor (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, & Others)– Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2019 – 2027

Report ID :AMI-259 | Category : Healthcare | Published Date : July, 2019 | Pages : 363 | Format :PDF
Buy Now!

Industry Trends

Global non-insulin therapies for diabetes market was valued at US$ 61,090.1 million in 2018 and is estimated to reach US$ 105,461.5 million by 2027, growing at a CAGR of 6.3% over the forecast period.

Global Non-Insulin Therapies for Diabetes Market Revenue, 2015 - 2027

Global Non-Insulin Therapies for Diabetes Market

Increasing demand for combination therapy and rapid advancements in diabetes treatment are fueling the global non-insulin therapies for diabetes market growth. Combination therapies such as administration of anti-hyperglycemic drugs alone or in combination with insulin used for the treatment of type 2 diabetes. Moreover, from the demand side, surge in people suffering from type 2 diabetes happens to be the primary reason behind growing adoption of various non-insulin therapies across the globe.

As per International Diabetes Foundation (IDF), in 2017, the global prevalence of diabetic patients stood at 425 million, of which 400 million were suffering from type 2 diabetes. Moreover, according to the World Health Organization (WHO), in 2017, diabetes was among top three cause of death with more than 30 million cases in the U.S. alone.

Technological advancements expected to be key growth enabler in the non-insulin therapies for diabetes market. Key vendors operating in the market developed technology platforms such as protein oral delivery (POD) technology (Oramed Pharmaceuticals), Eligen (Emisphere Technologies), Axcess (Diabetology), and PharmFilm Technology (MonoSol Rx) for oral administration of GLP-1 agonists. Moreover, companies such as Panacea and ScinoPharm are in the early stage development of oral capsules for the DPP4 inhibitors. 

However, patent expiries of the currently available drugs, and the potential health hazards associated with the use of these inhibitors proves to be major hurdle in market expansion path.

Thiazolidinediones, Insulin secretagogues, alpha-glucosidase inhibitors (AGIs), Sulfonylureas, dipeptidyl peptidase-4 (DPP-4) inhibitors, Glinides/Meglitinides, Amylin agonists, Metformin, Glucagon like peptide-1 (GLP-1) agonists, and Biguanides are some of the products used in the non-insulin therapies for diabetes market. Oral product segment held the largest market share in 2018 and it is estimated to expand at a rapid rate over the projection period. The growth is attributed to the presence of more oral drugs in the market.

North America non-insulin therapies for diabetes market, held largest market share and is estimated to hold its dominance in years to come. As per the International Diabetes Foundation (IDF), in the U.S. alone approximately, 17,100 new cases of diabetes were reported. This high incidence rate is driving the market growth in the concerned region.

Asia Pacific non-insulin therapies for diabetes market is the most lucrative, owing to surge in diabetes burden in India and China. Both countries collectively has more than 180 million people suffering from diabetes. Moreover, according to the American Diabetes Association (ADA), incidence rate of type 2 diabetes in South East Asia is expected to be more than 150%, by 2035.

The report provides both, qualitative and quantitative research of global non-insulin therapies for diabetes market, it also provides penetrative insights into the rational scenario and favored development methods adopted by key contenders. The report also offers extensive research on the key players in the market and detailed insights into the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by major players are also recognized and analyzed in the report. For each company, the report recognizes its headquarter, competitors, product/service type, application and specification, pricing, and gross margin.

Competitive Landscape

Major industry participants in global non-insulin therapies for diabetes market include Eli Lilly and Company, Eurofarma Laboratorios S.A., GlaxoSmithKline plc, Merck Sharp & Dohme Corp. (subsidiary of Merck & Co., Inc), Novo Nordisk, Luye Pharma Group, and Pfizer Inc. among others. New product launches, merger and acquisition, geographical expansion are some of the major strategies adopted by these players to gain a competitive edge.

  • By Product
    • Oral
      • Thiazolidinediones (TZDs)
      • Insulin secretagogues
      • Alpha-glucosidase inhibitors (AGIs)
      • Sulfonylureas
      • Dipeptidyl peptidase-4 (DPP-4) inhibitors
      • Sodium-glucose cotransporter-2 (SGLT2) inhibitors
      • Glinides/Meglitinides
      • Metformin
      • Biguanides
      • Others
    • Injectable
      • Glucagon-like peptide-1 (GLP-1) agonists
      • Amylin Agonists
      • Others
  • By Distributor
    • Hospital Pharmacy
    • Retail Pharmacies
    • Online Pharmacy
    • Others
  • By Geography
    • North America
      • U.S.
      • Canada
      • Mexico
      • Rest of North America
    • Asia Pacific
      • China
      • Japan
      • India
      • New Zealand
      • Australia
      • South Korea
      • Southeast Asia
        • Indonesia
        • Thailand
        • Malaysia
        • Singapore
        • Rest of Southeast Asia
      • Rest of Asia Pacific
    • Europe
      • France
      • The UK
      • Spain
      • Germany
      • Italy
      • Nordic Countries
        • Denmark
        • Finland
        • Iceland
        • Sweden
        • Norway
      • Benelux Union
        • Belgium
        • The Netherlands
        • Luxembourg
      • Rest of Europe
    • Middle East and Africa
      • Saudi Arabia
      • UAE
      • Egypt
      • Kuwait
      • South Africa
      • Rest of Middle East & Africa
    • Latin America
      • Argentina
      • Brazil
      • Rest of Latin America

Key Questions

Request Sample

Report Customization

Request for Customization

1.    Market Scope

1.1. Market Segmentation

1.2. Years Considered

1.2.1. Historic Years: 2013 - 2017

1.2.2. Base Year: 2018

1.2.3. Forecast Years: 2019 – 2027

2.    Key Target Audiences

3.    Research Methodology

3.1. Primary Research

3.1.1. Research Questionnaire

3.1.2. Global Percentage Breakdown

3.1.3. Primary Interviews: Key Opinion Leaders (KOLs)

3.2. Secondary Research

3.2.1. Paid Databases

3.2.2. Secondary Sources

3.3. Market Size Estimates

3.3.1. Top-Down Approach

3.3.2. Bottom-Up Approach

3.4. Data Triangulation Methodology

3.5. Research Assumptions

4.    Recommendations and Insights from AMI’s Perspective**

5.    Holistic Overview of Non-Insulin Therapies for Diabetes Market

6.    Market Synopsis:  Non-Insulin Therapies for Diabetes Market

7.    Non-Insulin Therapies for Diabetes Market Analysis: Qualitative Perspective

7.1. Introduction

7.1.1. Product Definition

7.1.2. Industry Development

7.2. Market Dynamics

7.2.1. Drivers

7.2.2. Restraints

7.2.3. Opportunities

7.3. Trends in Non-Insulin Therapies for Diabetes Market

7.4. Market Determinants Radar Chart

7.5. Macro-Economic and Micro-Economic Indicators: Non-Insulin Therapies for Diabetes Market

7.6. Industry Gross Margin Overview

7.7. Porter’s Five Force Analysis

8.    Global Non-Insulin Therapies for Diabetes Market Analysis and Forecasts, 2019 – 2027

8.1. Overview

8.1.1. Global Non-Insulin Therapies for Diabetes Market Revenue (US$ Mn)

8.2. Global Non-Insulin Therapies for Diabetes Market Revenue (US$ Mn) and Forecasts, By Product

8.2.1. Oral (Definition, Market Penetration (2018), Market Estimation (2013 – 2018), Market Forecast (2019 – 2027), Compound Annual Growth Rate (CAGR), Regional Bifurcation (North America, Europe, Asia Pacific, Middle East and Africa, Latin America) and Information on Thiazolidinediones (TZDs))

8.2.1.1.    Thiazolidinediones (TZDs)

8.2.1.1.1.    Insulin secretagogues

8.2.1.1.2.    Alpha-glucosidase inhibitors (AGIs)

8.2.1.1.3.    Sulfonylureas

8.2.1.1.4.    Dipeptidyl peptidase-4 (DPP-4) inhibitors

8.2.1.1.5.    Sodium-glucose cotransporter-2 (SGLT2) inhibitors

8.2.1.1.6.    Glinides / Meglitinides

8.2.1.1.7.    Metformin

8.2.1.1.8.    Biguanides

8.2.1.1.9.    Others

8.2.2. Injectable (Definition, Market Penetration (2018), Market Estimation (2013 – 2018), Market Forecast (2019 – 2027), Compound Annual Growth Rate (CAGR), Regional Bifurcation (North America, Europe, Asia Pacific, Middle East and Africa, Latin America) and Information on Glucagon-like peptide-1 (GLP-1) agonists, Amylin Agonists, Others)

8.2.2.1.    Glucagon-like peptide-1 (GLP-1) agonists

8.2.2.2.    Amylin Agonists

8.2.2.3.    Others

8.3. Key Segment for Channeling Investments

8.3.1. By Product

9.    Global Non-Insulin Therapies for Diabetes Market Analysis and Forecasts, 2019 – 2027

9.1. Overview

9.2. Global Non-Insulin Therapies for Diabetes Market Revenue (US$ Mn) and Forecasts, By Distributer

9.2.1. Hospital Pharmacy

9.2.1.1.    Definition

9.2.1.2.    Market Penetration, 2018

9.2.1.3.    Market Estimation, 2013 – 2018

9.2.1.4.    Market Forecast, 2019 – 2027

9.2.1.5.    Compound Annual Growth Rate (CAGR)

9.2.1.6.    Regional Bifurcation

9.2.1.6.1.    North America

9.2.1.6.1.1. Market Estimation, 2013 – 2018

9.2.1.6.1.2. Market Forecast, 2019 – 2027

9.2.1.6.2.    Europe

9.2.1.6.2.1. Market Estimation, 2013 – 2018

9.2.1.6.2.2. Market Forecast, 2019 – 2027

9.2.1.6.3.    Asia Pacific

9.2.1.6.3.1. Market Estimation, 2013 – 2018

9.2.1.6.3.2. Market Forecast, 2019 – 2027

9.2.1.6.4.    Middle East and Africa

9.2.1.6.4.1. Market Estimation, 2013 – 2018

9.2.1.6.4.2. Market Forecast, 2019 – 2027

9.2.1.6.5.    Latin America

9.2.1.6.5.1. Market Estimation, 2013 – 2018

9.2.1.6.5.2. Market Forecast, 2019 – 2027

9.2.2. Retail Pharmacies

9.2.2.1.    Definition

9.2.2.2.    Market Penetration, 2018

9.2.2.3.    Market Estimation, 2013 – 2018

9.2.2.4.    Market Forecast, 2019 – 2027

9.2.2.5.    Compound Annual Growth Rate (CAGR)

9.2.2.6.    Regional Bifurcation

9.2.2.6.1.    North America

9.2.2.6.1.1. Market Estimation, 2013 – 2018

9.2.2.6.1.2. Market Forecast, 2019 – 2027

9.2.2.6.2.    Europe

9.2.2.6.2.1. Market Estimation, 2013 – 2018

9.2.2.6.2.2. Market Forecast, 2019 – 2027

9.2.2.6.3.    Asia Pacific

9.2.2.6.3.1. Market Estimation, 2013 – 2018

9.2.2.6.3.2. Market Forecast, 2019 – 2027

9.2.2.6.4.    Middle East and Africa

9.2.2.6.4.1. Market Estimation, 2013 – 2018

9.2.2.6.4.2. Market Forecast, 2019 – 2027

9.2.2.6.5.    Latin America

9.2.2.6.5.1. Market Estimation, 2013 – 2018

9.2.2.6.5.2. Market Forecast, 2019 – 2027

9.2.3. Online Pharmacy

9.2.3.1.    Definition

9.2.3.2.    Market Penetration, 2018

9.2.3.3.    Market Estimation, 2013 – 2018

9.2.3.4.    Market Forecast, 2019 – 2027

9.2.3.5.    Compound Annual Growth Rate (CAGR)

9.2.3.6.    Regional Bifurcation

9.2.3.6.1.    North America

9.2.3.6.1.1. Market Estimation, 2013 – 2018

9.2.3.6.1.2. Market Forecast, 2019 – 2027

9.2.3.6.2.    Europe

9.2.3.6.2.1. Market Estimation, 2013 – 2018

9.2.3.6.2.2. Market Forecast, 2019 – 2027

9.2.3.6.3.    Asia Pacific

9.2.3.6.3.1. Market Estimation, 2013 – 2018

9.2.3.6.3.2. Market Forecast, 2019 – 2027

9.2.3.6.4.    Middle East and Africa

9.2.3.6.4.1. Market Estimation, 2013 – 2018

9.2.3.6.4.2. Market Forecast, 2019 – 2027

9.2.3.6.5.    Latin America

9.2.3.6.5.1. Market Estimation, 2013 – 2018

9.2.3.6.5.2. Market Forecast, 2019 – 2027

9.2.4. Others

9.2.4.1.    Definition

9.2.4.2.    Market Penetration, 2018

9.2.4.3.    Market Estimation, 2013 – 2018

9.2.4.4.    Market Forecast, 2019 – 2027

9.2.4.5.    Compound Annual Growth Rate (CAGR)

9.2.4.6.    Regional Bifurcation

9.2.4.6.1.    North America

9.2.4.6.1.1. Market Estimation, 2013 – 2018

9.2.4.6.1.2. Market Forecast, 2019 – 2027

9.2.4.6.2.    Europe

9.2.4.6.2.1. Market Estimation, 2013 – 2018

9.2.4.6.2.2. Market Forecast, 2019 – 2027

9.2.4.6.3.    Asia Pacific

9.2.4.6.3.1. Market Estimation, 2013 – 2018

9.2.4.6.3.2. Market Forecast, 2019 – 2027

9.2.4.6.4.    Middle East and Africa

9.2.4.6.4.1. Market Estimation, 2013 – 2018

9.2.4.6.4.2. Market Forecast, 2019 – 2027

9.2.4.6.5.    Latin America

9.2.4.6.5.1. Market Estimation, 2013 – 2018

9.2.4.6.5.2. Market Forecast, 2019 – 2027

9.3. Key Segment for Channeling Investments

9.3.1. By Distributer

10. North America Non-Insulin Therapies for Diabetes Market Analysis and Forecasts, 2019 - 2027

10.1. Overview

10.1.1. North America Non-Insulin Therapies for Diabetes Market Revenue (US$ Mn)

10.2. North America Non-Insulin Therapies for Diabetes Market Revenue (US$ Mn) and Forecasts, By Product

10.2.1. Oral

10.2.1.1.  Thiazolidinediones (TZDs)

10.2.1.1.1.  Insulin secretagogues

10.2.1.1.2.  Alpha-glucosidase inhibitors (AGIs)

10.2.1.1.3.  Sulfonylureas

10.2.1.1.4.  Dipeptidyl peptidase-4 (DPP-4) inhibitors

10.2.1.1.5.  Sodium-glucose cotransporter-2 (SGLT2) inhibitors

10.2.1.1.6.  Glinides / Meglitinides

10.2.1.1.7.  Metformin

10.2.1.1.8.  Biguanides

10.2.1.1.9.  Others

10.2.2. Injectable

10.2.2.1.  Glucagon-like peptide-1 (GLP-1) agonists

10.2.2.2.  Amylin Agonists

10.2.2.3.  Others

10.3. North America Non-Insulin Therapies for Diabetes Market Revenue (US$ Mn) and Forecasts, By Distributer

10.3.1. Hospital Pharmacy

10.3.2. Retail Pharmacies

10.3.3. Online Pharmacy

10.3.4. Others

10.4. North America Non-Insulin Therapies for Diabetes Market Revenue (US$ Mn) and Forecasts, By Country

10.4.1. U.S

10.4.1.1.  U.S Non-Insulin Therapies for Diabetes Market Revenue (US$ Mn) and Forecasts, By Product

10.4.1.1.1.  Oral

10.4.1.1.1.1. Thiazolidinediones (TZDs)

10.4.1.1.1.1.1. Insulin secretagogues

10.4.1.1.1.1.2. Alpha-glucosidase inhibitors (AGIs)

10.4.1.1.1.1.3. Sulfonylureas

10.4.1.1.1.1.4. Dipeptidyl peptidase-4 (DPP-4) inhibitors

10.4.1.1.1.1.5. Sodium-glucose cotransporter-2 (SGLT2) inhibitors

10.4.1.1.1.1.6. Glinides / Meglitinides

10.4.1.1.1.1.7. Metformin

10.4.1.1.1.1.8. Biguanides

10.4.1.1.1.1.9. Others

10.4.1.1.2.  Injectable

10.4.1.1.2.1. Glucagon-like peptide-1 (GLP-1) agonists

10.4.1.1.2.2. Amylin Agonists

10.4.1.1.2.3. Others

10.4.1.2.  U.S Non-Insulin Therapies for Diabetes Market Revenue (US$ Mn) and Forecasts, By Distributer

10.4.1.2.1.  Hospital Pharmacy

10.4.1.2.2.  Retail Pharmacies

10.4.1.2.3.  Online Pharmacy

10.4.1.2.4.  Others

10.4.2. Canada

10.4.2.1.  Canada Non-Insulin Therapies for Diabetes Market Revenue (US$ Mn) and Forecasts, By Product

10.4.2.1.1.  Oral

10.4.2.1.1.1. Thiazolidinediones (TZDs)

10.4.2.1.1.1.1. Insulin secretagogues

10.4.2.1.1.1.2. Alpha-glucosidase inhibitors (AGIs)

10.4.2.1.1.1.3. Sulfonylureas

10.4.2.1.1.1.4. Dipeptidyl peptidase-4 (DPP-4) inhibitors

10.4.2.1.1.1.5. Sodium-glucose cotransporter-2 (SGLT2) inhibitors

10.4.2.1.1.1.6. Glinides / Meglitinides

10.4.2.1.1.1.7. Metformin

10.4.2.1.1.1.8. Biguanides

10.4.2.1.1.1.9. Others

10.4.2.1.2.  Injectable

10.4.2.1.2.1. Glucagon-like peptide-1 (GLP-1) agonists

10.4.2.1.2.2. Amylin Agonists

10.4.2.1.2.3. Others

10.4.2.2.  Canada Non-Insulin Therapies for Diabetes Market Revenue (US$ Mn) and Forecasts, By Distributer

10.4.2.2.1.  Hospital Pharmacy

10.4.2.2.2.  Retail Pharmacies

10.4.2.2.3.  Online Pharmacy

10.4.2.2.4.  Others

10.4.3. Mexico

10.4.3.1.  Mexico Non-Insulin Therapies for Diabetes Market Revenue (US$ Mn) and Forecasts, By Product

10.4.3.1.1.  Oral

10.4.3.1.1.1. Thiazolidinediones (TZDs)

10.4.3.1.1.1.1. Insulin secretagogues

10.4.3.1.1.1.2. Alpha-glucosidase inhibitors (AGIs)

10.4.3.1.1.1.3. Sulfonylureas

10.4.3.1.1.1.4. Dipeptidyl peptidase-4 (DPP-4) inhibitors

10.4.3.1.1.1.5. Sodium-glucose cotransporter-2 (SGLT2) inhibitors

10.4.3.1.1.1.6. Glinides / Meglitinides

10.4.3.1.1.1.7. Metformin

10.4.3.1.1.1.8. Biguanides

10.4.3.1.1.1.9. Others

10.4.3.1.2.  Injectable

10.4.3.1.2.1. Glucagon-like peptide-1 (GLP-1) agonists

10.4.3.1.2.2. Amylin Agonists

10.4.3.1.2.3. Others

10.4.3.2.  Mexico Non-Insulin Therapies for Diabetes Market Revenue (US$ Mn) and Forecasts, By Distributer

10.4.3.2.1.  Hospital Pharmacy

10.4.3.2.2.  Retail Pharmacies

10.4.3.2.3.  Online Pharmacy

10.4.3.2.4.  Others

10.4.4. Rest of North America

10.4.4.1.  Rest of North America Non-Insulin Therapies for Diabetes Market Revenue (US$ Mn) and Forecasts, By Product

10.4.4.1.1.  Oral

10.4.4.1.1.1. Thiazolidinediones (TZDs)

10.4.4.1.1.1.1. Insulin secretagogues

10.4.4.1.1.1.2. Alpha-glucosidase inhibitors (AGIs)

10.4.4.1.1.1.3. Sulfonylureas

10.4.4.1.1.1.4. Dipeptidyl peptidase-4 (DPP-4) inhibitors

10.4.4.1.1.1.5. Sodium-glucose cotransporter-2 (SGLT2) inhibitors

10.4.4.1.1.1.6. Glinides / Meglitinides

10.4.4.1.1.1.7. Metformin

10.4.4.1.1.1.8. Biguanides

10.4.4.1.1.1.9. Others

10.4.4.1.2.  Injectable

10.4.4.1.2.1. Glucagon-like peptide-1 (GLP-1) agonists

10.4.4.1.2.2. Amylin Agonists

10.4.4.1.2.3. Others

10.4.4.2.  Rest of North America Non-Insulin Therapies for Diabetes Market Revenue (US$ Mn) and Forecasts, By Distributer

10.4.4.2.1.  Hospital Pharmacy

10.4.4.2.2.  Retail Pharmacies

10.4.4.2.3.  Online Pharmacy

10.4.4.2.4.  Others

10.5. Key Segment for Channeling Investments

10.5.1. By Country

10.5.2. By Product

10.5.3. By Distributer

11. Europe Non-Insulin Therapies for Diabetes Market Analysis and Forecasts, 2019 - 2027

11.1. Overview

11.1.1. Europe Non-Insulin Therapies for Diabetes Market Revenue (US$ Mn)

11.2. Europe Non-Insulin Therapies for Diabetes Market Revenue (US$ Mn) and Forecasts, By Product

11.2.1. Oral

11.2.1.1.  Thiazolidinediones (TZDs)

11.2.1.1.1.  Insulin secretagogues

11.2.1.1.2.  Alpha-glucosidase inhibitors (AGIs)

11.2.1.1.3.  Sulfonylureas

11.2.1.1.4.  Dipeptidyl peptidase-4 (DPP-4) inhibitors

11.2.1.1.5.  Sodium-glucose cotransporter-2 (SGLT2) inhibitors

11.2.1.1.6.  Glinides / Meglitinides

11.2.1.1.7.  Metformin

11.2.1.1.8.  Biguanides

11.2.1.1.9.  Others

11.2.2. Injectable

11.2.2.1.  Glucagon-like peptide-1 (GLP-1) agonists

11.2.2.2.  Amylin Agonists

11.2.2.3.  Others

11.3. Europe Non-Insulin Therapies for Diabetes Market Revenue (US$ Mn) and Forecasts, By Distributer

11.3.1. Hospital Pharmacy

11.3.2. Retail Pharmacies

11.3.3. Online Pharmacy

11.3.4. Others

11.4. Europe Non-Insulin Therapies for Diabetes Market Revenue (US$ Mn) and Forecasts, By Country

11.4.1. France

11.4.1.1.  France Non-Insulin Therapies for Diabetes Market Revenue (US$ Mn) and Forecasts, By Product

11.4.1.1.1.  Oral

11.4.1.1.1.1. Thiazolidinediones (TZDs)

11.4.1.1.1.1.1. Insulin secretagogues

11.4.1.1.1.1.2. Alpha-glucosidase inhibitors (AGIs)

11.4.1.1.1.1.3. Sulfonylureas

11.4.1.1.1.1.4. Dipeptidyl peptidase-4 (DPP-4) inhibitors

11.4.1.1.1.1.5. Sodium-glucose cotransporter-2 (SGLT2) inhibitors

11.4.1.1.1.1.6. Glinides / Meglitinides

11.4.1.1.1.1.7. Metformin

11.4.1.1.1.1.8. Biguanides

11.4.1.1.1.1.9. Others

11.4.1.1.2.  Injectable

11.4.1.1.2.1. Glucagon-like peptide-1 (GLP-1) agonists

11.4.1.1.2.2. Amylin Agonists

11.4.1.1.2.3. Others

11.4.1.2.  France Non-Insulin Therapies for Diabetes Market Revenue (US$ Mn) and Forecasts, By Distributer

11.4.1.2.1.  Hospital Pharmacy

11.4.1.2.2.  Retail Pharmacies

11.4.1.2.3.  Online Pharmacy

11.4.1.2.4.  Others

11.4.2. The UK

11.4.2.1.  The UK Non-Insulin Therapies for Diabetes Market Revenue (US$ Mn) and Forecasts, By Product

11.4.2.1.1.  Oral

11.4.2.1.1.1. Thiazolidinediones (TZDs)

11.4.2.1.1.1.1. Insulin secretagogues

11.4.2.1.1.1.2. Alpha-glucosidase inhibitors (AGIs)

11.4.2.1.1.1.3. Sulfonylureas

11.4.2.1.1.1.4. Dipeptidyl peptidase-4 (DPP-4) inhibitors

11.4.2.1.1.1.5. Sodium-glucose cotransporter-2 (SGLT2) inhibitors

11.4.2.1.1.1.6. Glinides / Meglitinides

11.4.2.1.1.1.7. Metformin

11.4.2.1.1.1.8. Biguanides

11.4.2.1.1.1.9. Others

11.4.2.1.2.  Injectable

11.4.2.1.2.1. Glucagon-like peptide-1 (GLP-1) agonists

11.4.2.1.2.2. Amylin Agonists

11.4.2.1.2.3. Others

11.4.2.2.  The UK Non-Insulin Therapies for Diabetes Market Revenue (US$ Mn) and Forecasts, By Distributer

11.4.2.2.1.  Hospital Pharmacy

11.4.2.2.2.  Retail Pharmacies

11.4.2.2.3.  Online Pharmacy

11.4.2.2.4.  Others

11.4.3. Spain

11.4.3.1.  Spain Non-Insulin Therapies for Diabetes Market Revenue (US$ Mn) and Forecasts, By Product

11.4.3.1.1.  Oral

11.4.3.1.1.1. Thiazolidinediones (TZDs)

11.4.3.1.1.1.1. Insulin secretagogues

11.4.3.1.1.1.2. Alpha-glucosidase inhibitors (AGIs)

11.4.3.1.1.1.3. Sulfonylureas

11.4.3.1.1.1.4. Dipeptidyl peptidase-4 (DPP-4) inhibitors

11.4.3.1.1.1.5. Sodium-glucose cotransporter-2 (SGLT2) inhibitors

11.4.3.1.1.1.6. Glinides / Meglitinides

11.4.3.1.1.1.7. Metformin

11.4.3.1.1.1.8. Biguanides

11.4.3.1.1.1.9. Others

11.4.3.1.2.  Injectable

11.4.3.1.2.1. Glucagon-like peptide-1 (GLP-1) agonists

11.4.3.1.2.2. Amylin Agonists

11.4.3.1.2.3. Others

11.4.3.2.  Spain Non-Insulin Therapies for Diabetes Market Revenue (US$ Mn) and Forecasts, By Distributer

11.4.3.2.1.  Hospital Pharmacy

11.4.3.2.2.  Retail Pharmacies

11.4.3.2.3.  Online Pharmacy

11.4.3.2.4.  Others

11.4.4. Germany

11.4.4.1.  Germany Non-Insulin Therapies for Diabetes Market Revenue (US$ Mn) and Forecasts, By Product

11.4.4.1.1.  Oral

11.4.4.1.1.1. Thiazolidinediones (TZDs)

11.4.4.1.1.1.1. Insulin secretagogues

11.4.4.1.1.1.2. Alpha-glucosidase inhibitors (AGIs)

11.4.4.1.1.1.3. Sulfonylureas

11.4.4.1.1.1.4. Dipeptidyl peptidase-4 (DPP-4) inhibitors

11.4.4.1.1.1.5. Sodium-glucose cotransporter-2 (SGLT2) inhibitors

11.4.4.1.1.1.6. Glinides / Meglitinides

11.4.4.1.1.1.7. Metformin

11.4.4.1.1.1.8. Biguanides

11.4.4.1.1.1.9. Others

11.4.4.1.2.  Injectable

11.4.4.1.2.1. Glucagon-like peptide-1 (GLP-1) agonists

11.4.4.1.2.2. Amylin Agonists

11.4.4.1.2.3. Others

11.4.4.2.  Germany Non-Insulin Therapies for Diabetes Market Revenue (US$ Mn) and Forecasts, By Distributer

11.4.4.2.1.  Hospital Pharmacy

11.4.4.2.2.  Retail Pharmacies

11.4.4.2.3.  Online Pharmacy

11.4.4.2.4.  Others

11.4.5. Italy

11.4.5.1.  Italy Non-Insulin Therapies for Diabetes Market Revenue (US$ Mn) and Forecasts, By Product

11.4.5.1.1.  Oral

11.4.5.1.1.1. Thiazolidinediones (TZDs)

11.4.5.1.1.1.1. Insulin secretagogues

11.4.5.1.1.1.2. Alpha-glucosidase inhibitors (AGIs)

11.4.5.1.1.1.3. Sulfonylureas

11.4.5.1.1.1.4. Dipeptidyl peptidase-4 (DPP-4) inhibitors

11.4.5.1.1.1.5. Sodium-glucose cotransporter-2 (SGLT2) inhibitors

11.4.5.1.1.1.6. Glinides / Meglitinides

11.4.5.1.1.1.7. Metformin

11.4.5.1.1.1.8. Biguanides

11.4.5.1.1.1.9. Others

11.4.5.1.2.  Injectable

11.4.5.1.2.1. Glucagon-like peptide-1 (GLP-1) agonists

11.4.5.1.2.2. Amylin Agonists

11.4.5.1.2.3. Others

11.4.5.2.  Italy Non-Insulin Therapies for Diabetes Market Revenue (US$ Mn) and Forecasts, By Distributer

11.4.5.2.1.  Hospital Pharmacy

11.4.5.2.2.  Retail Pharmacies

11.4.5.2.3.  Online Pharmacy

11.4.5.2.4.  Others

11.4.6. Nordic Countries

11.4.6.1.  Nordic Countries Non-Insulin Therapies for Diabetes Market Revenue (US$ Mn) and Forecasts, By Product

11.4.6.1.1.  Oral

11.4.6.1.1.1. Thiazolidinediones (TZDs)

11.4.6.1.1.1.1. Insulin secretagogues

11.4.6.1.1.1.2. Alpha-glucosidase inhibitors (AGIs)

11.4.6.1.1.1.3. Sulfonylureas

11.4.6.1.1.1.4. Dipeptidyl peptidase-4 (DPP-4) inhibitors

11.4.6.1.1.1.5. Sodium-glucose cotransporter-2 (SGLT2) inhibitors

11.4.6.1.1.1.6. Glinides / Meglitinides

11.4.6.1.1.1.7. Metformin

11.4.6.1.1.1.8. Biguanides

11.4.6.1.1.1.9. Others

11.4.6.1.2.  Injectable

11.4.6.1.2.1. Glucagon-like peptide-1 (GLP-1) agonists

11.4.6.1.2.2. Amylin Agonists

11.4.6.1.2.3. Others

11.4.6.2.  Nordic Countries Non-Insulin Therapies for Diabetes Market Revenue (US$ Mn) and Forecasts, By Distributer

11.4.6.2.1.  Hospital Pharmacy

11.4.6.2.2.  Retail Pharmacies

11.4.6.2.3.  Online Pharmacy

11.4.6.2.4.  Others

11.4.6.3.  Nordic Countries Non-Insulin Therapies for Diabetes Market Revenue (US$ Mn) and Forecasts, By Country

11.4.6.3.1.  Denmark

11.4.6.3.2.  Finland

11.4.6.3.3.  Iceland

11.4.6.3.4.  Sweden

11.4.6.3.5.  Norway

11.4.7. Benelux Union

11.4.7.1.  Benelux Union Non-Insulin Therapies for Diabetes Market Revenue (US$ Mn) and Forecasts, By Product

11.4.7.1.1.  Oral

11.4.7.1.1.1. Thiazolidinediones (TZDs)

11.4.7.1.1.1.1. Insulin secretagogues

11.4.7.1.1.1.2. Alpha-glucosidase inhibitors (AGIs)

11.4.7.1.1.1.3. Sulfonylureas

11.4.7.1.1.1.4. Dipeptidyl peptidase-4 (DPP-4) inhibitors

11.4.7.1.1.1.5. Sodium-glucose cotransporter-2 (SGLT2) inhibitors

11.4.7.1.1.1.6. Glinides / Meglitinides

11.4.7.1.1.1.7. Metformin

11.4.7.1.1.1.8. Biguanides

11.4.7.1.1.1.9. Others

11.4.7.1.2.  Injectable

11.4.7.1.2.1. Glucagon-like peptide-1 (GLP-1) agonists

11.4.7.1.2.2. Amylin Agonists

11.4.7.1.2.3. Others

11.4.7.2.  Benelux Union Non-Insulin Therapies for Diabetes Market Revenue (US$ Mn) and Forecasts, By Distributer

11.4.7.2.1.  Hospital Pharmacy

11.4.7.2.2.  Retail Pharmacies

11.4.7.2.3.  Online Pharmacy

11.4.7.2.4.  Others

11.4.7.3.  Benelux Union Non-Insulin Therapies for Diabetes Market Revenue (US$ Mn) and Forecasts, By Country

11.4.7.3.1.  Belgium

11.4.7.3.2.  The Netherlands

11.4.7.3.3.  Luxembourg

11.4.8. Rest of Europe

11.4.8.1.  Rest of Europe Non-Insulin Therapies for Diabetes Market Revenue (US$ Mn) and Forecasts, By Product

11.4.8.1.1.  Oral

11.4.8.1.1.1. Thiazolidinediones (TZDs)

11.4.8.1.1.1.1. Insulin secretagogues

11.4.8.1.1.1.2. Alpha-glucosidase inhibitors (AGIs)

11.4.8.1.1.1.3. Sulfonylureas

11.4.8.1.1.1.4. Dipeptidyl peptidase-4 (DPP-4) inhibitors

11.4.8.1.1.1.5. Sodium-glucose cotransporter-2 (SGLT2) inhibitors

11.4.8.1.1.1.6. Glinides / Meglitinides

11.4.8.1.1.1.7. Metformin

11.4.8.1.1.1.8. Biguanides

11.4.8.1.1.1.9. Others

11.4.8.1.2.  Injectable

11.4.8.1.2.1. Glucagon-like peptide-1 (GLP-1) agonists

11.4.8.1.2.2. Amylin Agonists

11.4.8.1.2.3. Others

11.4.8.2.  Rest of Europe Non-Insulin Therapies for Diabetes Market Revenue (US$ Mn) and Forecasts, By Distributer

11.4.8.2.1.  Hospital Pharmacy

11.4.8.2.2.  Retail Pharmacies

11.4.8.2.3.  Online Pharmacy

11.4.8.2.4.  Others

11.5. Key Segment for Channeling Investments

11.5.1. By Country

11.5.2. By Product

11.5.3. By Distributer

12. Asia Pacific Non-Insulin Therapies for Diabetes Market Analysis and Forecasts, 2019 - 2027

12.1. Overview

12.1.1. Asia Pacific Non-Insulin Therapies for Diabetes Market Revenue (US$ Mn)

12.2. Asia Pacific Non-Insulin Therapies for Diabetes Market Revenue (US$ Mn) and Forecasts, By Product

12.2.1. Oral

12.2.1.1.  Thiazolidinediones (TZDs)

12.2.1.1.1.  Insulin secretagogues

12.2.1.1.2.  Alpha-glucosidase inhibitors (AGIs)

12.2.1.1.3.  Sulfonylureas

12.2.1.1.4.  Dipeptidyl peptidase-4 (DPP-4) inhibitors

12.2.1.1.5.  Sodium-glucose cotransporter-2 (SGLT2) inhibitors

12.2.1.1.6.  Glinides / Meglitinides

12.2.1.1.7.  Metformin

12.2.1.1.8.  Biguanides

12.2.1.1.9.  Others

12.2.2. Injectable

12.2.2.1.  Glucagon-like peptide-1 (GLP-1) agonists

12.2.2.2.  Amylin Agonists

12.2.2.3.  Others

12.3. Asia Pacific Non-Insulin Therapies for Diabetes Market Revenue (US$ Mn) and Forecasts, By Distributer

12.3.1. Hospital Pharmacy

12.3.2. Retail Pharmacies

12.3.3. Online Pharmacy

12.3.4. Others

12.4. Asia Pacific Non-Insulin Therapies for Diabetes Market Revenue (US$ Mn) and Forecasts, By Country

12.4.1. China

12.4.1.1.  China Non-Insulin Therapies for Diabetes Market Revenue (US$ Mn) and Forecasts, By Product

12.4.1.1.1.  Oral

12.4.1.1.1.1. Thiazolidinediones (TZDs)

12.4.1.1.1.1.1. Insulin secretagogues

12.4.1.1.1.1.2. Alpha-glucosidase inhibitors (AGIs)

12.4.1.1.1.1.3. Sulfonylureas

12.4.1.1.1.1.4. Dipeptidyl peptidase-4 (DPP-4) inhibitors

12.4.1.1.1.1.5. Sodium-glucose cotransporter-2 (SGLT2) inhibitors

12.4.1.1.1.1.6. Glinides / Meglitinides

12.4.1.1.1.1.7. Metformin

12.4.1.1.1.1.8. Biguanides

12.4.1.1.1.1.9. Others

12.4.1.1.2.  Injectable

12.4.1.1.2.1. Glucagon-like peptide-1 (GLP-1) agonists

12.4.1.1.2.2. Amylin Agonists

12.4.1.1.2.3. Others

12.4.1.2.  China Non-Insulin Therapies for Diabetes Market Revenue (US$ Mn) and Forecasts, By Distributer

12.4.1.2.1.  Hospital Pharmacy

12.4.1.2.2.  Retail Pharmacies

12.4.1.2.3.  Online Pharmacy

12.4.1.2.4.  Others

12.4.2. Japan

12.4.2.1.  Japan Non-Insulin Therapies for Diabetes Market Revenue (US$ Mn) and Forecasts, By Product

12.4.2.1.1.  Oral

12.4.2.1.1.1. Thiazolidinediones (TZDs)

12.4.2.1.1.1.1. Insulin secretagogues

12.4.2.1.1.1.2. Alpha-glucosidase inhibitors (AGIs)

12.4.2.1.1.1.3. Sulfonylureas

12.4.2.1.1.1.4. Dipeptidyl peptidase-4 (DPP-4) inhibitors

12.4.2.1.1.1.5. Sodium-glucose cotransporter-2 (SGLT2) inhibitors

12.4.2.1.1.1.6. Glinides / Meglitinides

12.4.2.1.1.1.7. Metformin

12.4.2.1.1.1.8. Biguanides

12.4.2.1.1.1.9. Others

12.4.2.1.2.  Injectable

12.4.2.1.2.1. Glucagon-like peptide-1 (GLP-1) agonists

12.4.2.1.2.2. Amylin Agonists

12.4.2.1.2.3. Others

12.4.2.2.  Japan Non-Insulin Therapies for Diabetes Market Revenue (US$ Mn) and Forecasts, By Distributer

12.4.2.2.1.  Hospital Pharmacy

12.4.2.2.2.  Retail Pharmacies

12.4.2.2.3.  Online Pharmacy

12.4.2.2.4.  Others

12.4.3. India

12.4.3.1.  India Non-Insulin Therapies for Diabetes Market Revenue (US$ Mn) and Forecasts, By Product

12.4.3.1.1.  Oral

12.4.3.1.1.1. Thiazolidinediones (TZDs)

12.4.3.1.1.1.1. Insulin secretagogues

12.4.3.1.1.1.2. Alpha-glucosidase inhibitors (AGIs)

12.4.3.1.1.1.3. Sulfonylureas

12.4.3.1.1.1.4. Dipeptidyl peptidase-4 (DPP-4) inhibitors

12.4.3.1.1.1.5. Sodium-glucose cotransporter-2 (SGLT2) inhibitors

12.4.3.1.1.1.6. Glinides / Meglitinides

12.4.3.1.1.1.7. Metformin

12.4.3.1.1.1.8. Biguanides

12.4.3.1.1.1.9. Others

12.4.3.1.2.  Injectable

12.4.3.1.2.1. Glucagon-like peptide-1 (GLP-1) agonists

12.4.3.1.2.2. Amylin Agonists

12.4.3.1.2.3. Others

12.4.3.2.  India Non-Insulin Therapies for Diabetes Market Revenue (US$ Mn) and Forecasts, By Distributer

12.4.3.2.1.  Hospital Pharmacy

12.4.3.2.2.  Retail Pharmacies

12.4.3.2.3.  Online Pharmacy

12.4.3.2.4.  Others

12.4.4. New Zealand

12.4.4.1.  New Zealand Non-Insulin Therapies for Diabetes Market Revenue (US$ Mn) and Forecasts, By Product

12.4.4.1.1.  Oral

12.4.4.1.1.1. Thiazolidinediones (TZDs)

12.4.4.1.1.1.1. Insulin secretagogues

12.4.4.1.1.1.2. Alpha-glucosidase inhibitors (AGIs)

12.4.4.1.1.1.3. Sulfonylureas

12.4.4.1.1.1.4. Dipeptidyl peptidase-4 (DPP-4) inhibitors

12.4.4.1.1.1.5. Sodium-glucose cotransporter-2 (SGLT2) inhibitors

12.4.4.1.1.1.6. Glinides / Meglitinides

12.4.4.1.1.1.7. Metformin

12.4.4.1.1.1.8. Biguanides

12.4.4.1.1.1.9. Others

12.4.4.1.2.  Injectable

12.4.4.1.2.1. Glucagon-like peptide-1 (GLP-1) agonists

12.4.4.1.2.2. Amylin Agonists

12.4.4.1.2.3. Others

12.4.4.2.  New Zealand Non-Insulin Therapies for Diabetes Market Revenue (US$ Mn) and Forecasts, By Distributer

12.4.4.2.1.  Hospital Pharmacy

12.4.4.2.2.  Retail Pharmacies

12.4.4.2.3.  Online Pharmacy

12.4.4.2.4.  Others

12.4.5. Australia

12.4.5.1.  Australia Non-Insulin Therapies for Diabetes Market Revenue (US$ Mn) and Forecasts, By Product

12.4.5.1.1.  Oral

12.4.5.1.1.1. Thiazolidinediones (TZDs)

12.4.5.1.1.1.1. Insulin secretagogues

12.4.5.1.1.1.2. Alpha-glucosidase inhibitors (AGIs)

12.4.5.1.1.1.3. Sulfonylureas

12.4.5.1.1.1.4. Dipeptidyl peptidase-4 (DPP-4) inhibitors

12.4.5.1.1.1.5. Sodium-glucose cotransporter-2 (SGLT2) inhibitors

12.4.5.1.1.1.6. Glinides / Meglitinides

12.4.5.1.1.1.7. Metformin

12.4.5.1.1.1.8. Biguanides

12.4.5.1.1.1.9. Others

12.4.5.1.2.  Injectable

12.4.5.1.2.1. Glucagon-like peptide-1 (GLP-1) agonists

12.4.5.1.2.2. Amylin Agonists

12.4.5.1.2.3. Others

12.4.5.2.  Australia Non-Insulin Therapies for Diabetes Market Revenue (US$ Mn) and Forecasts, By Distributer

12.4.5.2.1.  Hospital Pharmacy

12.4.5.2.2.  Retail Pharmacies

12.4.5.2.3.  Online Pharmacy

12.4.5.2.4.  Others

12.4.6. South Korea

12.4.6.1.  South Korea Non-Insulin Therapies for Diabetes Market Revenue (US$ Mn) and Forecasts, By Product

12.4.6.1.1.  Oral

12.4.6.1.1.1. Thiazolidinediones (TZDs)

12.4.6.1.1.1.1. Insulin secretagogues

12.4.6.1.1.1.2. Alpha-glucosidase inhibitors (AGIs)

12.4.6.1.1.1.3. Sulfonylureas

12.4.6.1.1.1.4. Dipeptidyl peptidase-4 (DPP-4) inhibitors

12.4.6.1.1.1.5. Sodium-glucose cotransporter-2 (SGLT2) inhibitors

12.4.6.1.1.1.6. Glinides / Meglitinides

12.4.6.1.1.1.7. Metformin

12.4.6.1.1.1.8. Biguanides

12.4.6.1.1.1.9. Others

12.4.6.1.2.  Injectable

12.4.6.1.2.1. Glucagon-like peptide-1 (GLP-1) agonists

12.4.6.1.2.2. Amylin Agonists

12.4.6.1.2.3. Others

12.4.6.2.  South Korea Non-Insulin Therapies for Diabetes Market Revenue (US$ Mn) and Forecasts, By Distributer

12.4.6.2.1.  Hospital Pharmacy

12.4.6.2.2.  Retail Pharmacies

12.4.6.2.3.  Online Pharmacy

12.4.6.2.4.  Others

12.4.7. Southeast Asia

12.4.7.1.  Southeast Asia Non-Insulin Therapies for Diabetes Market Revenue (US$ Mn) and Forecasts, By Product

12.4.7.1.1.  Oral

12.4.7.1.1.1. Thiazolidinediones (TZDs)

12.4.7.1.1.1.1. Insulin secretagogues

12.4.7.1.1.1.2. Alpha-glucosidase inhibitors (AGIs)

12.4.7.1.1.1.3. Sulfonylureas

12.4.7.1.1.1.4. Dipeptidyl peptidase-4 (DPP-4) inhibitors

12.4.7.1.1.1.5. Sodium-glucose cotransporter-2 (SGLT2) inhibitors

12.4.7.1.1.1.6. Glinides / Meglitinides

12.4.7.1.1.1.7. Metformin

12.4.7.1.1.1.8. Biguanides

12.4.7.1.1.1.9. Others

12.4.7.1.2.  Injectable

12.4.7.1.2.1. Glucagon-like peptide-1 (GLP-1) agonists

12.4.7.1.2.2. Amylin Agonists

12.4.7.1.2.3. Others

12.4.7.2.  Southeast Asia Non-Insulin Therapies for Diabetes Market Revenue (US$ Mn) and Forecasts, By Distributer

12.4.7.2.1.  Hospital Pharmacy

12.4.7.2.2.  Retail Pharmacies

12.4.7.2.3.  Online Pharmacy

12.4.7.2.4.  Others

12.4.7.3.  Southeast Asia Non-Insulin Therapies for Diabetes Market Revenue (US$ Mn) and Forecasts, By Country

12.4.7.3.1.  Indonesia

12.4.7.3.2.  Thailand

12.4.7.3.3.  Malaysia

12.4.7.3.4.  Singapore

12.4.7.3.5.  Rest of Southeast Asia

12.4.8. Rest of Asia Pacific

12.4.8.1.  Rest of Asia Pacific Non-Insulin Therapies for Diabetes Market Revenue (US$ Mn) and Forecasts, By Product

12.4.8.1.1.  Oral

12.4.8.1.1.1. Thiazolidinediones (TZDs)

12.4.8.1.1.1.1. Insulin secretagogues

12.4.8.1.1.1.2. Alpha-glucosidase inhibitors (AGIs)

12.4.8.1.1.1.3. Sulfonylureas

12.4.8.1.1.1.4. Dipeptidyl peptidase-4 (DPP-4) inhibitors

12.4.8.1.1.1.5. Sodium-glucose cotransporter-2 (SGLT2) inhibitors

12.4.8.1.1.1.6. Glinides / Meglitinides

12.4.8.1.1.1.7. Metformin

12.4.8.1.1.1.8. Biguanides

12.4.8.1.1.1.9. Others

12.4.8.1.2.  Injectable

12.4.8.1.2.1. Glucagon-like peptide-1 (GLP-1) agonists

12.4.8.1.2.2. Amylin Agonists

12.4.8.1.2.3. Others

12.4.8.2.  Rest of Asia Pacific Non-Insulin Therapies for Diabetes Market Revenue (US$ Mn) and Forecasts, By Distributer

12.4.8.2.1.  Hospital Pharmacy

12.4.8.2.2.  Retail Pharmacies

12.4.8.2.3.  Online Pharmacy

12.4.8.2.4.  Others

12.5. Key Segment for Channeling Investments

12.5.1. By Country

12.5.2. By Product

12.5.3. By Distributer

13. Middle East and Africa Non-Insulin Therapies for Diabetes Market Analysis and Forecasts, 2019 - 2027

13.1. Overview

13.1.1. Middle East and Africa Non-Insulin Therapies for Diabetes Market Revenue (US$ Mn)

13.2. Middle East and Africa Non-Insulin Therapies for Diabetes Market Revenue (US$ Mn) and Forecasts, By Product

13.2.1. Oral

13.2.1.1.  Thiazolidinediones (TZDs)

13.2.1.1.1.  Insulin secretagogues

13.2.1.1.2.  Alpha-glucosidase inhibitors (AGIs)

13.2.1.1.3.  Sulfonylureas

13.2.1.1.4.  Dipeptidyl peptidase-4 (DPP-4) inhibitors

13.2.1.1.5.  Sodium-glucose cotransporter-2 (SGLT2) inhibitors

13.2.1.1.6.  Glinides / Meglitinides

13.2.1.1.7.  Metformin

13.2.1.1.8.  Biguanides

13.2.1.1.9.  Others

13.2.2. Injectable

13.2.2.1.  Glucagon-like peptide-1 (GLP-1) agonists

13.2.2.2.  Amylin Agonists

13.2.2.3.  Others

13.3. Middle East and Africa Non-Insulin Therapies for Diabetes Market Revenue (US$ Mn) and Forecasts, By Distributer

13.3.1. Hospital Pharmacy

13.3.2. Retail Pharmacies

13.3.3. Online Pharmacy

13.3.4. Others

13.4. Middle East and Africa Non-Insulin Therapies for Diabetes Market Revenue (US$ Mn) and Forecasts, By Country

13.4.1. Saudi Arabia

13.4.1.1.  Saudi Arabia Non-Insulin Therapies for Diabetes Market Revenue (US$ Mn) and Forecasts, By Product

13.4.1.1.1.  Oral

13.4.1.1.1.1. Thiazolidinediones (TZDs)

13.4.1.1.1.1.1. Insulin secretagogues

13.4.1.1.1.1.2. Alpha-glucosidase inhibitors (AGIs)

13.4.1.1.1.1.3. Sulfonylureas

13.4.1.1.1.1.4. Dipeptidyl peptidase-4 (DPP-4) inhibitors

13.4.1.1.1.1.5. Sodium-glucose cotransporter-2 (SGLT2) inhibitors

13.4.1.1.1.1.6. Glinides / Meglitinides

13.4.1.1.1.1.7. Metformin

13.4.1.1.1.1.8. Biguanides

13.4.1.1.1.1.9. Others

13.4.1.1.2.  Injectable

13.4.1.1.2.1. Glucagon-like peptide-1 (GLP-1) agonists

13.4.1.1.2.2. Amylin Agonists

13.4.1.1.2.3. Others

13.4.1.2.  Saudi Arabia Non-Insulin Therapies for Diabetes Market Revenue (US$ Mn) and Forecasts, By Distributer

13.4.1.2.1.  Hospital Pharmacy

13.4.1.2.2.  Retail Pharmacies

13.4.1.2.3.  Online Pharmacy

13.4.1.2.4.  Others

13.4.2. UAE

13.4.2.1.  UAE Non-Insulin Therapies for Diabetes Market Revenue (US$ Mn) and Forecasts, By Product

13.4.2.1.1.  Oral

13.4.2.1.1.1. Thiazolidinediones (TZDs)

13.4.2.1.1.1.1. Insulin secretagogues

13.4.2.1.1.1.2. Alpha-glucosidase inhibitors (AGIs)

13.4.2.1.1.1.3. Sulfonylureas

13.4.2.1.1.1.4. Dipeptidyl peptidase-4 (DPP-4) inhibitors

13.4.2.1.1.1.5. Sodium-glucose cotransporter-2 (SGLT2) inhibitors

13.4.2.1.1.1.6. Glinides / Meglitinides

13.4.2.1.1.1.7. Metformin

13.4.2.1.1.1.8. Biguanides

13.4.2.1.1.1.9. Others

13.4.2.1.2.  Injectable

13.4.2.1.2.1. Glucagon-like peptide-1 (GLP-1) agonists

13.4.2.1.2.2. Amylin Agonists

13.4.2.1.2.3. Others

13.4.2.2.  UAE Non-Insulin Therapies for Diabetes Market Revenue (US$ Mn) and Forecasts, By Distributer

13.4.2.2.1.  Hospital Pharmacy

13.4.2.2.2.  Retail Pharmacies

13.4.2.2.3.  Online Pharmacy

13.4.2.2.4.  Others

13.4.3. Egypt

13.4.3.1.  Egypt Non-Insulin Therapies for Diabetes Market Revenue (US$ Mn) and Forecasts, By Product

13.4.3.1.1.  Oral

13.4.3.1.1.1. Thiazolidinediones (TZDs)

13.4.3.1.1.1.1. Insulin secretagogues

13.4.3.1.1.1.2. Alpha-glucosidase inhibitors (AGIs)

13.4.3.1.1.1.3. Sulfonylureas

13.4.3.1.1.1.4. Dipeptidyl peptidase-4 (DPP-4) inhibitors

13.4.3.1.1.1.5. Sodium-glucose cotransporter-2 (SGLT2) inhibitors

13.4.3.1.1.1.6. Glinides / Meglitinides

13.4.3.1.1.1.7. Metformin

13.4.3.1.1.1.8. Biguanides

13.4.3.1.1.1.9. Others

13.4.3.1.2.  Injectable

13.4.3.1.2.1. Glucagon-like peptide-1 (GLP-1) agonists

13.4.3.1.2.2. Amylin Agonists

13.4.3.1.2.3. Others

13.4.3.2.  Egypt Non-Insulin Therapies for Diabetes Market Revenue (US$ Mn) and Forecasts, By Distributer

13.4.3.2.1.  Hospital Pharmacy

13.4.3.2.2.  Retail Pharmacies

13.4.3.2.3.  Online Pharmacy

13.4.3.2.4.  Others

13.4.4. Kuwait

13.4.4.1.  Kuwait Non-Insulin Therapies for Diabetes Market Revenue (US$ Mn) and Forecasts, By Product

13.4.4.1.1.  Oral

13.4.4.1.1.1. Thiazolidinediones (TZDs)

13.4.4.1.1.1.1. Insulin secretagogues

13.4.4.1.1.1.2. Alpha-glucosidase inhibitors (AGIs)

13.4.4.1.1.1.3. Sulfonylureas

13.4.4.1.1.1.4. Dipeptidyl peptidase-4 (DPP-4) inhibitors

13.4.4.1.1.1.5. Sodium-glucose cotransporter-2 (SGLT2) inhibitors

13.4.4.1.1.1.6. Glinides / Meglitinides

13.4.4.1.1.1.7. Metformin

13.4.4.1.1.1.8. Biguanides

13.4.4.1.1.1.9. Others

13.4.4.1.2.  Injectable

13.4.4.1.2.1. Glucagon-like peptide-1 (GLP-1) agonists

13.4.4.1.2.2. Amylin Agonists

13.4.4.1.2.3. Others

13.4.4.2.  Kuwait Non-Insulin Therapies for Diabetes Market Revenue (US$ Mn) and Forecasts, By Distributer

13.4.4.2.1.  Hospital Pharmacy

13.4.4.2.2.  Retail Pharmacies

13.4.4.2.3.  Online Pharmacy

13.4.4.2.4.  Others

13.4.5. South Africa

13.4.5.1.  South Africa Non-Insulin Therapies for Diabetes Market Revenue (US$ Mn) and Forecasts, By Product

13.4.5.1.1.  Oral

13.4.5.1.1.1. Thiazolidinediones (TZDs)

13.4.5.1.1.1.1. Insulin secretagogues

13.4.5.1.1.1.2. Alpha-glucosidase inhibitors (AGIs)

13.4.5.1.1.1.3. Sulfonylureas

13.4.5.1.1.1.4. Dipeptidyl peptidase-4 (DPP-4) inhibitors

13.4.5.1.1.1.5. Sodium-glucose cotransporter-2 (SGLT2) inhibitors

13.4.5.1.1.1.6. Glinides / Meglitinides

13.4.5.1.1.1.7. Metformin

13.4.5.1.1.1.8. Biguanides

13.4.5.1.1.1.9. Others

13.4.5.1.2.  Injectable

13.4.5.1.2.1. Glucagon-like peptide-1 (GLP-1) agonists

13.4.5.1.2.2. Amylin Agonists

13.4.5.1.2.3. Others

13.4.5.2.  South Africa Non-Insulin Therapies for Diabetes Market Revenue (US$ Mn) and Forecasts, By Distributer

13.4.5.2.1.  Hospital Pharmacy

13.4.5.2.2.  Retail Pharmacies

13.4.5.2.3.  Online Pharmacy

13.4.5.2.4.  Others

13.4.6. Rest of Middle East & Africa

13.4.6.1.  Rest of Middle East & Africa Non-Insulin Therapies for Diabetes Market Revenue (US$ Mn) and Forecasts, By Product

13.4.6.1.1.  Oral

13.4.6.1.1.1. Thiazolidinediones (TZDs)

13.4.6.1.1.1.1. Insulin secretagogues

13.4.6.1.1.1.2. Alpha-glucosidase inhibitors (AGIs)

13.4.6.1.1.1.3. Sulfonylureas

13.4.6.1.1.1.4. Dipeptidyl peptidase-4 (DPP-4) inhibitors

13.4.6.1.1.1.5. Sodium-glucose cotransporter-2 (SGLT2) inhibitors

13.4.6.1.1.1.6. Glinides / Meglitinides

13.4.6.1.1.1.7. Metformin

13.4.6.1.1.1.8. Biguanides

13.4.6.1.1.1.9. Others

13.4.6.1.2.  Injectable

13.4.6.1.2.1. Glucagon-like peptide-1 (GLP-1) agonists

13.4.6.1.2.2. Amylin Agonists

13.4.6.1.2.3. Others

13.4.6.2.  Rest of Middle East & Africa Non-Insulin Therapies for Diabetes Market Revenue (US$ Mn) and Forecasts, By Distributer

13.4.6.2.1.  Hospital Pharmacy

13.4.6.2.2.  Retail Pharmacies

13.4.6.2.3.  Online Pharmacy

13.4.6.2.4.  Others

13.5. Key Segment for Channeling Investments

13.5.1. By Country

13.5.2. By Product

13.5.3. By Distributer

14. Latin America Non-Insulin Therapies for Diabetes Market Analysis and Forecasts, 2019 - 2027

14.1. Overview

14.1.1. Latin America Non-Insulin Therapies for Diabetes Market Revenue (US$ Mn)

14.2. Latin America Non-Insulin Therapies for Diabetes Market Revenue (US$ Mn) and Forecasts, By Product

14.2.1. Oral

14.2.1.1.  Thiazolidinediones (TZDs)

14.2.1.1.1.  Insulin secretagogues

14.2.1.1.2.  Alpha-glucosidase inhibitors (AGIs)

14.2.1.1.3.  Sulfonylureas

14.2.1.1.4.  Dipeptidyl peptidase-4 (DPP-4) inhibitors

14.2.1.1.5.  Sodium-glucose cotransporter-2 (SGLT2) inhibitors

14.2.1.1.6.  Glinides / Meglitinides

14.2.1.1.7.  Metformin

14.2.1.1.8.  Biguanides

14.2.1.1.9.  Others

14.2.2. Injectable

14.2.2.1.  Glucagon-like peptide-1 (GLP-1) agonists

14.2.2.2.  Amylin Agonists

14.2.2.3.  Others

14.3. Latin America Non-Insulin Therapies for Diabetes Market Revenue (US$ Mn) and Forecasts, By Distributer

14.3.1. Hospital Pharmacy

14.3.2. Retail Pharmacies

14.3.3. Online Pharmacy

14.3.4. Others

14.4. Latin America Non-Insulin Therapies for Diabetes Market Revenue (US$ Mn) and Forecasts, By Country

14.4.1. Brazil

14.4.1.1.  Brazil Non-Insulin Therapies for Diabetes Market Revenue (US$ Mn) and Forecasts, By Product

14.4.1.1.1.  Oral

14.4.1.1.1.1. Thiazolidinediones (TZDs)

14.4.1.1.1.1.1. Insulin secretagogues

14.4.1.1.1.1.2. Alpha-glucosidase inhibitors (AGIs)

14.4.1.1.1.1.3. Sulfonylureas

14.4.1.1.1.1.4. Dipeptidyl peptidase-4 (DPP-4) inhibitors

14.4.1.1.1.1.5. Sodium-glucose cotransporter-2 (SGLT2) inhibitors

14.4.1.1.1.1.6. Glinides / Meglitinides

14.4.1.1.1.1.7. Metformin

14.4.1.1.1.1.8. Biguanides

14.4.1.1.1.1.9. Others

14.4.1.1.2.  Injectable

14.4.1.1.2.1. Glucagon-like peptide-1 (GLP-1) agonists

14.4.1.1.2.2. Amylin Agonists

14.4.1.1.2.3. Others

14.4.1.2.  Brazil Non-Insulin Therapies for Diabetes Market Revenue (US$ Mn) and Forecasts, By Distributer

14.4.1.2.1.  Hospital Pharmacy

14.4.1.2.2.  Retail Pharmacies

14.4.1.2.3.  Online Pharmacy

14.4.1.2.4.  Others

14.4.2. Argentina

14.4.2.1.  Argentina Non-Insulin Therapies for Diabetes Market Revenue (US$ Mn) and Forecasts, By Product

14.4.2.1.1.  Oral

14.4.2.1.1.1. Thiazolidinediones (TZDs)

14.4.2.1.1.1.1. Insulin secretagogues

14.4.2.1.1.1.2. Alpha-glucosidase inhibitors (AGIs)

14.4.2.1.1.1.3. Sulfonylureas

14.4.2.1.1.1.4. Dipeptidyl peptidase-4 (DPP-4) inhibitors

14.4.2.1.1.1.5. Sodium-glucose cotransporter-2 (SGLT2) inhibitors

14.4.2.1.1.1.6. Glinides / Meglitinides

14.4.2.1.1.1.7. Metformin

14.4.2.1.1.1.8. Biguanides

14.4.2.1.1.1.9. Others

14.4.2.1.2.  Injectable

14.4.2.1.2.1. Glucagon-like peptide-1 (GLP-1) agonists

14.4.2.1.2.2. Amylin Agonists

14.4.2.1.2.3. Others

14.4.2.2.  Argentina Non-Insulin Therapies for Diabetes Market Revenue (US$ Mn) and Forecasts, By Distributer

14.4.2.2.1.  Hospital Pharmacy

14.4.2.2.2.  Retail Pharmacies

14.4.2.2.3.  Online Pharmacy

14.4.2.2.4.  Others

14.4.3. Rest of Latin America

14.4.3.1.  Rest of Latin America Non-Insulin Therapies for Diabetes Market Revenue (US$ Mn) and Forecasts, By Product

14.4.3.1.1.  Oral

14.4.3.1.1.1. Thiazolidinediones (TZDs)

14.4.3.1.1.1.1. Insulin secretagogues

14.4.3.1.1.1.2. Alpha-glucosidase inhibitors (AGIs)

14.4.3.1.1.1.3. Sulfonylureas

14.4.3.1.1.1.4. Dipeptidyl peptidase-4 (DPP-4) inhibitors

14.4.3.1.1.1.5. Sodium-glucose cotransporter-2 (SGLT2) inhibitors

14.4.3.1.1.1.6. Glinides / Meglitinides

14.4.3.1.1.1.7. Metformin

14.4.3.1.1.1.8. Biguanides

14.4.3.1.1.1.9. Others

14.4.3.1.2.  Injectable

14.4.3.1.2.1. Glucagon-like peptide-1 (GLP-1) agonists

14.4.3.1.2.2. Amylin Agonists

14.4.3.1.2.3. Others

14.4.3.2.  Rest of Latin America Non-Insulin Therapies for Diabetes Market Revenue (US$ Mn) and Forecasts, By Distributer

14.4.3.2.1.  Hospital Pharmacy

14.4.3.2.2.  Retail Pharmacies

14.4.3.2.3.  Online Pharmacy

14.4.3.2.4.  Others

14.5. Key Segment for Channeling Investments

14.5.1. By Country

14.5.2. By Product

14.5.3. By Distributer

15. Competitive Benchmarking

15.1. Brand Benchmarking

15.2. Market Share Analysis, 2018

15.3. Global Presence and Growth Strategies

15.3.1. Mergers and Acquisitions

15.3.2. Product Launches

15.3.3. Investments Trends

15.3.4. R&D Initiatives

16. Player Profiles

16.1. Alkem Labs.

16.1.1. Company Details

16.1.2. Company Overview

16.1.3. Product Offerings

16.1.4. Key Developments

16.1.5. Financial Analysis

16.1.6. SWOT Analysis

16.1.7. Business Strategies

16.2. Eli Lilly and Company

16.2.1. Company Details

16.2.2. Company Overview

16.2.3. Product Offerings

16.2.4. Key Developments

16.2.5. Financial Analysis

16.2.6. SWOT Analysis

16.2.7. Business Strategies

16.3. Emisphere Technologies

16.3.1. Company Details

16.3.2. Company Overview

16.3.3. Product Offerings

16.3.4. Key Developments

16.3.5. Financial Analysis

16.3.6. SWOT Analysis

16.3.7. Business Strategies

16.4. Eurofarma Laboratórios S.A.

16.4.1. Company Details

16.4.2. Company Overview

16.4.3. Product Offerings

16.4.4. Key Developments

16.4.5. Financial Analysis

16.4.6. SWOT Analysis

16.4.7. Business Strategies

16.5. GEROPHARM

16.5.1. Company Details

16.5.2. Company Overview

16.5.3. Product Offerings

16.5.4. Key Developments

16.5.5. Financial Analysis

16.5.6. SWOT Analysis

16.5.7. Business Strategies

16.6. GlaxoSmithKline plc.

16.6.1. Company Details

16.6.2. Company Overview

16.6.3. Product Offerings

16.6.4. Key Developments

16.6.5. Financial Analysis

16.6.6. SWOT Analysis

16.6.7. Business Strategies

16.7. Intarcia Therapeutics, Inc.

16.7.1. Company Details

16.7.2. Company Overview

16.7.3. Product Offerings

16.7.4. Key Developments

16.7.5. Financial Analysis

16.7.6. SWOT Analysis

16.7.7. Business Strategies

16.8. Jiangsu Hengrui Medicine

16.8.1. Company Details

16.8.2. Company Overview

16.8.3. Product Offerings

16.8.4. Key Developments

16.8.5. Financial Analysis

16.8.6. SWOT Analysis

16.8.7. Business Strategies

16.9. Luye Pharma Group

16.9.1. Company Details

16.9.2. Company Overview

16.9.3. Product Offerings

16.9.4. Key Developments

16.9.5. Financial Analysis

16.9.6. SWOT Analysis

16.9.7. Business Strategies

16.10. Merck Sharp & Dohme Corp.

16.10.1. Company Details

16.10.2. Company Overview

16.10.3. Product Offerings

16.10.4. Key Developments

16.10.5. Financial Analysis

16.10.6. SWOT Analysis

16.10.7. Business Strategies

16.11. Novo Nordisk

16.11.1. Company Details

16.11.2. Company Overview

16.11.3. Product Offerings

16.11.4. Key Developments

16.11.5. Financial Analysis

16.11.6. SWOT Analysis

16.11.7. Business Strategies

16.12. Pfizer Inc.

16.12.1. Company Details

16.12.2. Company Overview

16.12.3. Product Offerings

16.12.4. Key Developments

16.12.5. Financial Analysis

16.12.6. SWOT Analysis

16.12.7. Business Strategies

16.13. Satrix

16.13.1. Company Details

16.13.2. Company Overview

16.13.3. Product Offerings

16.13.4. Key Developments

16.13.5. Financial Analysis

16.13.6. SWOT Analysis

16.13.7. Business Strategies

16.14. Servier

16.14.1. Company Details

16.14.2. Company Overview

16.14.3. Product Offerings

16.14.4. Key Developments

16.14.5. Financial Analysis

16.14.6. SWOT Analysis

16.14.7. Business Strategies

16.15. Sumitomo Dainippon Pharma Co., Ltd.

16.15.1. Company Details

16.15.2. Company Overview

16.15.3. Product Offerings

16.15.4. Key Developments

16.15.5. Financial Analysis

16.15.6. SWOT Analysis

16.15.7. Business Strategies

16.16. Syneos Health

16.16.1. Company Details

16.16.2. Company Overview

16.16.3. Product Offerings

16.16.4. Key Developments

16.16.5. Financial Analysis

16.16.6. SWOT Analysis

16.16.7. Business Strategies

16.17. Takeda Pharmaceutical Company Limited

16.17.1. Company Details

16.17.2. Company Overview

16.17.3. Product Offerings

16.17.4. Key Developments

16.17.5. Financial Analysis

16.17.6. SWOT Analysis

16.17.7. Business Strategies

16.18. Other industry participants

17. Key Findings

 

Note: This ToC is tentative and can be changed according to the research study conducted during the course of report completion.

 

**Exclusive for Multi-User and Enterprise User.

 

At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.

Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews  are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.  

Prominent participants in our primary research process include:

  • Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
  • Research and development participants, distributors/suppliers and subject matter experts

Secondary Research includes data extracted from paid data sources:

  • Reuters
  • Factiva
  • Bloomberg
  • One Source
  • Hoovers

Research Methodology

Methodology

Key Inclusions

Methodology

  • A PHP Error was encountered

    Severity: Notice

    Message: Undefined offset: 0

    Filename: pages/reportpage.php

    Line Number: 163

    Backtrace:

    File: /var/www/html/ami/application/views/pages/reportpage.php
    Line: 163
    Function: _error_handler

    File: /var/www/html/ami/application/controllers/Report.php
    Line: 153
    Function: view

    File: /var/www/html/ami/index.php
    Line: 315
    Function: require_once